Effects of Antipsychotics on Bone Mineral Density in Patients with Schizophrenia: Gender Differences

키워드

참고문헌 (131)

1. Hugenholtz GW, "Risk of hip", femur fractures in patients using antipsychotics, 2005, pp.37, 864~870
2. Howard L, "Risk of hip fracture in patients with a history of schizophrenia", Br J Psychiatry, 190, pp.129~134 (2007)
3. Takahashi T, "The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia:findings from a longitudinal observational cohort", Schizophr Res, 147, pp.383~386 (2013)
4. Stubbs B, "Schizophrenia and the risk of fractures:a systematic review and comparative meta-analysis", Gen Hosp Psychiatry, 37, pp.126~133 (2015)
5. Holt RI, "Osteoporosis in people with severe mental illness:A forgotten condition", Maturitas, 67, pp.1~2 (2010)
6. Stubbs B, "A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia", Acta Psychiatr Scand, 130, pp.470~486 (2014)
7. Javaid MK, "Understanding osteoporosis", J Psychopharmacol, 22(2 Suppl), pp.38~45 (2008)
8. Simon JA, "Prevention and management of osteoporosis", Clin Cornerstone, (Suppl 2), pp.S5~S12 (2003)
9. Lorentzon M, "Osteoporosis: the evolution of a diagnosis", J Intern Med, 277, pp.650~661 (2015)
10. Golob AL, "Osteoporosis: screening, prevention, and management", Med Clin North Am, 99, pp.587~606 (2015)
11. Kanis JA, "Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report", Osteoporos Int, 4, pp.368~381 (1994), WHO Study Group
12. Meaney AM, "Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia", Br J Psychiatry, 184, pp.503~508 (2004)
13. O'Keane V, "Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?", J Clin Psychopharmacol, 25, pp.26~31 (2005)
14. Renn JH, "Bone mass in schizophrenia and normal populations across different decades of life", BMC Musculoskelet Disord, 10, pp.1~ (2009)
15. Gudelsky GA, "Tuberoinfundibular dopamine neurons and the regulation of prolactin secretion", Psychoneuroendocrinology, 6, pp.3~16 (1981)
16. Peveler RC, "Antipsychotics and hyperprolactinaemia:clinical recommendations", J Psychopharmacol, 22(2 Suppl), pp.98~103 (2008)
17. Kollin E, "Decreased bone density in hyperprolactinemic women", N Engl J Med, 304, pp.1362~1363 (1981)
18. Dickson RA, "Hormonal side effects in women: typical versus atypical antipsychotic treatment", J Clin Psychiatry, 61(Suppl 3), pp.10~15 (2000)
19. Klibanski A, "Effects of prolactin and estrogen deficiency in amenorrheic bone loss", J Clin Endocrinol Metab, 67, pp.124~130 (1988)
20. Kishimoto T, "Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia", J Clin Psychiatry, 69, pp.385~391 (2008)
21. Khosla S, "Estrogen and theskeleton", Trends Endocrinol Metab, 23, pp.576~581 (2012)
22. Kinon BJ, "Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine", Psychoneuroendocrinology, 31, pp.577~588 (2006)
23. Riggs BL, "Involutional osteoporosis", N Engl J Med, 314, pp.1676~1686 (1986)
24. Kenny AM, "Osteoporosis. Pathogenesis, diagnosis, and treatment in older adults", Rheum Dis Clin North Am, 26, pp.569~591 (2000)
25. Seriwatanachai D, "Evidence for direct effects of prolactin on human osteoblasts:Inhibition of cell growth and mineralization", J Cell Biochem, 107, pp.677~685 (2009)
26. Kanis JA, "Smoking and fracture risk: a metaanalysis", Osteoporos Int, 16, pp.155~162 (2005)
27. Gonnelli S, "Obesity and fracture risk", Clin Cases Miner Bone Metab, 11, pp.9~14 (2014)
28. Chesnut CH 3rd, "Bone mass and exercise", Am J Med, 95, pp.34S~36S (1993)
29. Holbrook TL, "A prospective study of alcohol consumption and bone mineral density", BMJ, 306, pp.1506~1509 (1993)
30. Cooper MS, "Glucocorticoids, bone and energy metabolism", Bone, 82, pp.64~68 (2016)
31. Pocock NA, "Genetic determinants of bone mass in adults. A twin study", J Clin Invest, 80, pp.706~710 (1987)
32. Burge RT, "The cost of osteoporotic fractures in the UK:projections for 2000-2020", J Med Econ, 4, pp.51~62 (2001)
33. Peet M, "Diet, diabetes and schizophrenia: review and hypothesis", Br J Psychiatry Suppl, 47, pp.S102~S105 (2004)
34. Wark JD, "Osteoporotic fractures: background and prevention strategies", Maturitas, 23, pp.193~207 (1996)
35. Crews MP, "Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications", Hum Psychopharmacol, 27, pp.15~23 (2012)
36. Kishimoto T, "Osteoporosis and fracture risk in people with schizophrenia", Curr Opin Psychiatry, 25, pp.415~429 (2012)
37. Soundy A, "Physical activity and sedentary behaviour in outpatients with schizophrenia: A systematic review and meta-analysis", Int J Ther Rehabil, 20, pp.588~595 (2013)
38. DE Hert M, "Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care", World Psychiatry, 10, pp.52~77 (2011)
39. Vancampfort D, "A meta-analysis of cardiometabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls", World Psychiatry, 12, pp.240~250 (2013)
40. Delva NJ, "Osteopenia, pathological fractures, and increased urinary calcium excretion in schizophrenic patients with polydipsia", Biol Psychiatry, 26, pp.781~793 (1989)
41. Doknic M, "Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone", Neuroendocrinology, 94, pp.246~254 (2011)
42. Hummer M, "Osteoporosis in patients with schizophrenia", Am J Psychiatry, 162, pp.162~167 (2005)
43. de Leon J, "A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors", Schizophr Res, 76, pp.135~157 (2005)
44. Jung DU, "Bone mineral density and osteoporosis risk in older patients with schizophrenia", J Clin Psychopharmacol, 31, pp.406~410 (2011)
45. Yoon V, "The effects of smoking on bone metabolism", Osteoporos Int, 23, pp.2081~2092 (2012)
46. Kessler RC, "The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R)", Biol Psychiatry, 58, pp.668~676 (2005)
47. Sampson HW, "Alcohol's harmful effects on bone", Alcohol Health Res World, 22, pp.190~194 (1998)
48. Janghorbani M, "Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture", Am J Epidemiol, 166, pp.495~505 (2007)
49. Dazzan P, "Neurological soft signs in firstepisode psychosis: a systematic review", Br J Psychiatry Suppl, 43, pp.s50~s57 (2002)
50. Partti K, "Skeletal status in psychotic disorders:a population-based study", Psychosom Med, 72, pp.933~940 (2010)
51. "NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference", South Med J, 94, pp.569~573 (2001)
52. Bonnick SL, "Bone densitometry in clinical practice:application and interpretation" (2010), Humana Press
53. Czerwiński E, "Radiologic diagnosis and densitometry of osteoporosis", Przegl Lek, 54, pp.220~225 (1997)
54. Kanis JA, "Diagnosis of osteoporosis and assessment of fracture risk", Lancet, 359, pp.1929~1936 (2002)
55. Leslie WD, "Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions", J Clin Densitom, 9, pp.22~30 (2006)
56. Binkley N, "Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005Position Development Conference", J Clin Densitom, 9, pp.4~14 (2006)
57. Heidari B, "Dual-energy X-ray absorptiometry diagnostic discordance between Z-scores and T-scores in a young Iranian population", Med J Islam Repub Iran, 28, pp.151~ (2014)
58. Swaminathan K, "Search for secondary osteoporosis: are Z scores useful predictors?", Postgrad Med J, 85, pp.38~39 (2009)
59. Carey JJ, "DXA-generated Z-scores and T-scores may differ substantially and significantly in youngadults", J Clin Densitom, 10, pp.351~358 (2007)
60. Gilsanz V, "Peak trabecular vertebral density: a comparison of adolescent and adult females", Calcif Tissue Int, 43, pp.260~262 (1988)
61. Farr JN, "Skeletal changes through the lifespan--from growth to senescence", Nat Rev Endocrinol, 11, pp.513~521 (2015)
62. Ferlin A, "Testicular function and bone metabolism--beyond testosterone", Nat Rev Endocrinol, 9, pp.548~554 (2013)
63. Mellström D, "Older men with low serum estradiol and high serum SHBG have an increased risk of fractures", J Bone Miner Res, 23, pp.1552~1560 (2008)
64. Amin S, "Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study", Am J Med, 119, pp.426~433 (2006)
65. Goderie-Plomp HW, "Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: the Rotterdam Study", J Clin Endocrinol Metab, 89, pp.3261~3269 (2004)
66. Falahati-Nini A, "Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men", J Clin Invest, 106, pp.1553~1560 (2000)
67. Hannemann A, "Osteocalcin is associated with testosterone in the general population and selected patients with bone disorders", Andrology, 1, pp.469~474 (2013)
68. Barrett-Connor E, "The association of concurrent vitamin D and sex hormone deficiency with bone loss and fracture risk in older men: the osteoporotic fractures in men (MrOS) study", J Bone Miner Res, 27, pp.2306~2313 (2012)
69. Cauley JA, "Estrogen and bone health in men and women", Steroids, 99, pp.11~15 (2015)
70. Irwig MS, "Bone health in hypogonadal men", Curr Opin Urol, 24, pp.608~613 (2014)
71. Watts NB, "Osteoporosis in men:an Endocrine Society clinical practice guideline", J Clin Endocrinol Metab, 97, pp.1802~1822 (2012)
72. Yarrow JF, "Testosterone and adult male bone: Actions independent of 5α-reductase and aromatase", Exerc Sport Sci Rev, 43, pp.222~230 (2015)
73. Smith EP, "Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man", N Engl J Med, 331, pp.1056~1061 (1994)
74. Morishima A, "Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens", J Clin Endocrinol Metab, 80, pp.3689~3698 (1995)
75. Arpaci D, "Serum testosterone does not affect bone mineral density in postmenopausal women", Arch Endocrinol Metab, 59, pp.292~296 (2015)
76. Khosla S, "Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen", J Clin Endocrinol Metab, 83, pp.2266~2274 (1998)
77. Kalantaridou SN, "Testosterone therapy in premenopausal women", Semin Reprod Med, 24, pp.106~114 (2006)
78. Hummer M, "Hyperprolactinaemia and antipsychotic therapy in schizophrenia", Curr Med Res Opin, 20, pp.189~197 (2004)
79. Lin CH, "Sex-specific factors for bone density in patients with schizophrenia", Int Clin Psychopharmacol, 30, pp.96~102 (2015)
80. Bushe C, "A review of the association between antipsychotic use and hyperprolactinaemia", J Psychopharmacol, 22(2 Suppl), pp.46~55 (2008)
81. Kinon BJ, "Bone loss associated with hyperprolactinemia in patients with schizophrenia", Clin Schizophr Relat Psychoses, 7, pp.115~123 (2013)
82. Kinon BJ, "Hyperprolactinemia in response to antipsychotic drugs : characterization across comparative clinical trials", Psychoneuroendocrinology, 28(Suppl 2), pp.69~82 (2003)
83. 이태영, "Bone Density in Chronic Schizophrenia with Long-Term Antipsychotic Treatment: Preliminary Study", PSYCHIATRY INVESTIGATION, 7(4), pp.278~284 (2010), 대한신경정신의학회
84. Jung DU, "Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study", J Clin Psychiatry, 67, pp.1391~1396 (2006)
85. Bergemann N, "High bone turnover but normal bone mineral density in women suffering from schizophrenia", Psychol Med, 38, pp.1195~1201 (2008)
86. Wei QS, "Serum osteopontin levels in relation to bone mineral density and bone turnover markers in postmenopausal women", Scand J Clin Lab Invest, 76, pp.33~39 (2016)
87. Bolton JM, "Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women", J Clin Psychopharmacol, 31, pp.56~60 (2011)
88. Greenspan SL, "Osteoporosis in men with hyperprolactinemic hypogonadism", Ann Intern Med, 104, pp.777~782 (1986)
89. Abraham G, "Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study", Am J Psychiatry, 160, pp.1618~1620 (2003)
90. Masi G, "Prolactin levels in young children with pervasive developmental disorders during risperidone treatment", J Child Adolesc Psychopharmacol, 11, pp.389~394 (2001)
91. Paparrigopoulos T, "Amisulpride-induced hyperprolactinemia is reversible following discontinuation", Prog Neuropsychopharmacol Biol Psychiatry, 31, pp.92~96 (2007)
92. Kearns AE, "Risperidone-associated hyperprolactinemia", Endocr Pract, 6, pp.425~429 (2000)
93. Plenge P, "Lithium effects on calcium, magnesium and phosphate in man: effects on balance, bone mineral content, faecal and urinary excretion", Acta Psychiatr Scand, 66, pp.361~373 (1982)
94. Zamani A, "Lithium's effect on bone mineral density", Bone, 44, pp.331~334 (2009)
95. Kerbage H, "Effect of SSRIs on bone metabolism", Encephale, 40, pp.56~61 (2014)
96. Ak E, "Evaluation of the effect of selective serotonin reuptake inhibitors on bone mineral density: an observational cross-sectional study", Osteoporos Int, 26, pp.273~279 (2015)
97. Misra M, "Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism", J Clin Psychiatry, 65, pp.1607~1618 (2004)
98. Yang S, "Association between beta-blockers and fracture risk: a Bayesian meta-analysis", Bone, 51, pp.969~974 (2012)
99. Bjarnason NH, "Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women", Bone, 26, pp.561~569 (2000)
100. Zaitseva OV, "Biochemical markers of bone collagen type I metabolism", Ukr Biochem J, 87, pp.21~32 (2015)
101. Christenson RH, "Biochemical markers of bone metabolism:an overview", Clin Biochem, 30, pp.573~593 (1997)
102. Tanaka K, "Serum levels of carboxyterminal propeptide of type I procollagen (PICP), cross-linked carboxyterminal telopeptide region of type I collagen (ICTP) and carboxyterminal parathyroid hormone-related protein (C-PTHrP) in hematological malignancies with bone lesions and hypercalcemia", Rinsho Ketsueki, 39, pp.273~280 (1998)
103. Fukunaga M, "Bone quality and bone metabolism (marker)", Clin Calcium, 14, pp.561~565 (2004)
104. Okita K, "Second-generation antipsychotics and bone turnover in schizophrenia", Schizophr Res, 157, pp.137~141 (2014)
105. Chen XX, "Roles of leptin in bone metabolism and bone diseases", J Bone Miner Metab, 33, pp.474~485 (2015)
106. Potvin S, "Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a metaanalysis", Can J Psychiatry, 60(3 Suppl 2), pp.S26~S34 (2015)
107. Ventriglio A, "Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management", Front Neurosci, 9, pp.297~ (2015)
108. Ducy P, "Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass", Cell, 100, pp.197~207 (2000)
109. Yadav VK, "A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure", Cell, 138, pp.976~989 (2009)
110. Leinninger GM, "Leptin acts via leptin receptor-expressing lateral hypothalamic neurons to modulate the mesolimbic dopamine system and suppress feeding", Cell Metab, 10, pp.89~98 (2009)
111. Takayanagi Y, "Relationships between serum leptin level and severity of positive symptoms in schizophrenia", Neurosci Res, 77, pp.97~101 (2013)
112. Liu-Seifert H, "Osteopenia associated with increased prolactin and aging in psychiatric patients treated with prolactin-elevating antipsychotics", Ann N Y Acad Sci, 1032, pp.297~298 (2004)
113. Sugawara N, "Effect of age and disease on bone mass in Japanese patients with schizophrenia", Ann Gen Psychiatry, 11, pp.5~ (2012)
114. "Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group", World Health Organ Tech Rep Ser, 843, pp.1~129 (1994)
115. Rariy CM, "Higher serum free testosterone concentration in older women is associated with greater bone mineral density, lean body mass, and total fat mass:the cardiovascular health study", J Clin Endocrinol Metab, 96, pp.989~996 (2011)
116. Paxton RJ, "Associations between body size and serum estradiol and sex hormone-binding globulin levels in premenopausal African American women", J Clin Endocrinol Metab, 98, pp.E485~E490 (2013)
117. Pappagallo M, "The effect of atypical antipsychotic agents on prolactin levels in children and adolescents", J Child Adolesc Psychopharmacol, 14, pp.359~371 (2004)
118. Colao A, "Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization", Clin Endocrinol (Oxf), 52, pp.319~327 (2000)
119. Cranney A, "Effectiveness and safety of vitamin D in relation to bone health", Evid Rep Technol Assess (Full Rep), (158), pp.1~235 (2007)
120. Howes OD, "Comment on Hyperprolactinaemia and antipsychotic therapy in schizophrenia", Curr Med Res Opin, 20, pp.1649~ (2004)
121. Hamner M, "The effects of atypical antipsychotics on serum prolactin levels", Ann Clin Psychiatry, 14, pp.163~173 (2002)
122. Klibanski A, "Decreased bone density in hyperprolactinemic women", N Engl J Med, 303, pp.1511~1514 (1980)
123. Gentile S, "Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications", Obes Rev, 10, pp.527~542 (2009)
124. Domecq JP, "Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis", J Clin Endocrinol Metab, 100, pp.363~370 (2015)
125. Bainbridge KE, "Risk factors for low bone mineral density and the 6-year rate of bone loss among premenopausal and perimenopausal women", Osteoporos Int, 15, pp.439~446 (2004)
126. Lin CH, "Clozapine protects bone mineral density in female patients with schizophrenia", Int J Neuropsychopharmacol, 15, pp.897~906 (2012)
127. Wang H, "Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-κB signaling pathways", Breast Cancer Res Treat, 149, pp.705~714 (2015)
128. Kawamura H, "Inhibitory effect of chlorpromazine on RANKL-induced osteoclastogenesis in mouse bone marrow cells", J Pharmacol Sci, 117, pp.54~62 (2011)
129. Meaney AM, "Bone mineral density changesover a year in young females with schizophrenia: relationship to medication and endocrine variables", Schizophr Res, 93, pp.136~143 (2007)
130. Walther S, "Objectively measured motor activity in schizophrenia challenges the validity of expert ratings", Psychiatry Res, 169, pp.187~190 (2009)
131. Vancampfort D, "The functional exercise capacity is correlated with global functioning in patients with schizophrenia", Acta Psychiatr Scand, 125, pp.382~387 (2012)

관련 논문AI추천